Physician profile
Marc E Wietschner
NPI 1477555829
$3,896.12
in general payments reported to CMS, 2019-2025
22 companies · $637 in 2025
The $637 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $324 · 2021: $459 · 2022: $483 · 2023: $680 · 2024: $786 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,102.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $902.62 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Aerie Pharmaceuticals, INC. | $457.42 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $322.24 | 2019-2021 | |
| Oyster Point Pharma, INC. | $312.74 | 2022-2025 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $276.13 | 2021-2025 | Acthar |
| Alcon Vision LLC | $263.10 | 2019-2025 | Simbrinza |
| Sun Pharmaceutical Industries INC. | $237.90 | 2021-2025 | Cequa, Xelpros |
| Allergan, INC. | $207.33 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $205.72 | 2022-2024 | Xiidra, Miebo, Vyzulta |
| Astellas Pharma US INC | $148.01 | 2023-2025 | Izervay |
| Biotissue Holdings INC. | $122.06 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $111.93 | 2019-2023 | |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Harrow Eye, LLC | $64.17 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $41.29 | 2025 | Xdemvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $31.26 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $30.80 | 2022 | |
| Amgen INC. | $25.72 | 2025 | Tepezza |
| Genentech USA, INC. | $24.24 | 2022 | |
| Shire North American Group INC | $21.39 | 2019 | |
| Horizon Therapeutics Plc | $17.34 | 2019 | |
| Optos, INC. | $8.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Wietschner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.